HK1243948A1 - 溴结构域抑制剂 - Google Patents
溴结构域抑制剂 Download PDFInfo
- Publication number
- HK1243948A1 HK1243948A1 HK18103550.6A HK18103550A HK1243948A1 HK 1243948 A1 HK1243948 A1 HK 1243948A1 HK 18103550 A HK18103550 A HK 18103550A HK 1243948 A1 HK1243948 A1 HK 1243948A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methylisoquinolin
- methylsulfonylphenyl
- cyclopropylmethoxy
- bromodomain inhibitor
- pharmaceutical compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562151205P | 2015-04-22 | 2015-04-22 | |
| US62/151,205 | 2015-04-22 | ||
| PCT/US2016/029029 WO2016172618A1 (en) | 2015-04-22 | 2016-04-22 | Bromodomain inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1243948A1 true HK1243948A1 (zh) | 2018-07-27 |
Family
ID=57143581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18103550.6A HK1243948A1 (zh) | 2015-04-22 | 2016-04-22 | 溴结构域抑制剂 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20160310423A1 (enExample) |
| EP (1) | EP3285770A4 (enExample) |
| JP (1) | JP2018513863A (enExample) |
| KR (1) | KR20170139119A (enExample) |
| CN (1) | CN107613981A (enExample) |
| AR (1) | AR104340A1 (enExample) |
| AU (1) | AU2016252992A1 (enExample) |
| BR (1) | BR112017022691A2 (enExample) |
| CA (1) | CA2983446C (enExample) |
| CL (1) | CL2017002679A1 (enExample) |
| CO (1) | CO2017011482A2 (enExample) |
| EA (1) | EA201792317A1 (enExample) |
| EC (1) | ECSP17071545A (enExample) |
| HK (1) | HK1243948A1 (enExample) |
| IL (1) | IL255120B (enExample) |
| MX (2) | MX390077B (enExample) |
| PE (1) | PE20180036A1 (enExample) |
| PH (1) | PH12017501933A1 (enExample) |
| SG (1) | SG11201708627TA (enExample) |
| TW (1) | TW201642860A (enExample) |
| WO (1) | WO2016172618A1 (enExample) |
| ZA (1) | ZA201707186B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR104259A1 (es) | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
| US10702517B2 (en) | 2015-04-22 | 2020-07-07 | Celgene Quanticel Research, Inc. | Bromodomain inhibitor |
| GB201506872D0 (en) | 2015-04-22 | 2015-06-03 | Ge Oil & Gas Uk Ltd | Novel compounds |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| CN110099685A (zh) * | 2016-10-20 | 2019-08-06 | 赛尔基因光迪斯研究公司 | 溴结构域抑制剂 |
| HUE058289T2 (hu) | 2016-10-27 | 2022-07-28 | Celgene Quanticel Res Inc | Brómdomén és extraterminális protein inhibitor kombinációs terápia |
| AU2019309693B2 (en) * | 2018-07-23 | 2023-03-16 | Celgene Quanticel Research, Inc. | Process for the preparation of bromodomain inhibitor |
| EP4294397A1 (en) * | 2021-02-22 | 2023-12-27 | Celgene Quanticel Research, Inc. | Bromodomain (bet) inhibitor for use in treating prostate cancer |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| WO2013097052A1 (en) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| EP3290407B1 (en) * | 2013-10-18 | 2020-01-01 | Celgene Quanticel Research, Inc | Bromodomain inhibitors |
| CN110099685A (zh) * | 2016-10-20 | 2019-08-06 | 赛尔基因光迪斯研究公司 | 溴结构域抑制剂 |
-
2016
- 2016-04-19 TW TW105112168A patent/TW201642860A/zh unknown
- 2016-04-21 AR ARP160101100A patent/AR104340A1/es unknown
- 2016-04-22 PE PE2017002306A patent/PE20180036A1/es not_active Application Discontinuation
- 2016-04-22 HK HK18103550.6A patent/HK1243948A1/zh unknown
- 2016-04-22 CA CA2983446A patent/CA2983446C/en active Active
- 2016-04-22 CN CN201680032770.1A patent/CN107613981A/zh active Pending
- 2016-04-22 US US15/136,761 patent/US20160310423A1/en not_active Abandoned
- 2016-04-22 KR KR1020177033575A patent/KR20170139119A/ko active Pending
- 2016-04-22 EA EA201792317A patent/EA201792317A1/ru unknown
- 2016-04-22 WO PCT/US2016/029029 patent/WO2016172618A1/en not_active Ceased
- 2016-04-22 MX MX2020010899A patent/MX390077B/es unknown
- 2016-04-22 EP EP16784024.8A patent/EP3285770A4/en not_active Withdrawn
- 2016-04-22 JP JP2017554566A patent/JP2018513863A/ja active Pending
- 2016-04-22 BR BR112017022691-0A patent/BR112017022691A2/pt not_active Application Discontinuation
- 2016-04-22 AU AU2016252992A patent/AU2016252992A1/en not_active Abandoned
- 2016-04-22 SG SG11201708627TA patent/SG11201708627TA/en unknown
- 2016-04-22 MX MX2017013501A patent/MX377159B/es active IP Right Grant
-
2017
- 2017-10-18 IL IL255120A patent/IL255120B/en active IP Right Grant
- 2017-10-20 CL CL2017002679A patent/CL2017002679A1/es unknown
- 2017-10-23 ZA ZA2017/07186A patent/ZA201707186B/en unknown
- 2017-10-23 PH PH12017501933A patent/PH12017501933A1/en unknown
- 2017-10-26 EC ECIEPI201771545A patent/ECSP17071545A/es unknown
- 2017-11-08 CO CONC2017/0011482A patent/CO2017011482A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL255120B (en) | 2021-03-25 |
| CL2017002679A1 (es) | 2018-05-25 |
| PH12017501933A1 (en) | 2018-03-19 |
| MX390077B (es) | 2025-03-20 |
| KR20170139119A (ko) | 2017-12-18 |
| MX2020010899A (es) | 2022-02-15 |
| WO2016172618A1 (en) | 2016-10-27 |
| JP2018513863A (ja) | 2018-05-31 |
| CA2983446C (en) | 2024-04-09 |
| NZ736630A (en) | 2024-03-22 |
| IL255120A0 (en) | 2017-12-31 |
| CN107613981A (zh) | 2018-01-19 |
| CA2983446A1 (en) | 2016-10-27 |
| CO2017011482A2 (es) | 2018-01-31 |
| EA201792317A1 (ru) | 2018-03-30 |
| MX2017013501A (es) | 2018-02-09 |
| EP3285770A4 (en) | 2018-10-31 |
| TW201642860A (zh) | 2016-12-16 |
| ECSP17071545A (es) | 2017-12-01 |
| BR112017022691A2 (pt) | 2018-07-17 |
| AU2016252992A1 (en) | 2017-11-09 |
| EP3285770A1 (en) | 2018-02-28 |
| AR104340A1 (es) | 2017-07-12 |
| MX377159B (es) | 2025-03-07 |
| PE20180036A1 (es) | 2018-01-09 |
| SG11201708627TA (en) | 2017-11-29 |
| US20160310423A1 (en) | 2016-10-27 |
| ZA201707186B (en) | 2019-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017501933A1 (en) | Bromodomain inhibitor | |
| EP4285904A3 (en) | Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| WO2015168466A8 (en) | Inhibitors of lysine specific demethylase-1 | |
| WO2017100726A8 (en) | Methods for treating huntington's disease | |
| MX2016012574A (es) | Compuestos heteroarilo sustituidos y metodos de uso. | |
| EP4470614A3 (en) | Pharmaceutical compositions comprising meloxicam | |
| PL3331864T3 (pl) | Związki pochodne 1,3,4-oksadiazolu jako inhibitor deacetylazy histonowej 6 oraz zawierająca je kompozycja farmaceutyczna | |
| EP3484504A4 (en) | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATMENT OF DISEASE | |
| FI3328843T3 (fi) | 1,3,4-oksadiatsolisulfonamidijohdannaisyhdisteitä histonideasetylaasi-6:n inhibiittoreina ja samaa käsittävä farmaseuttinen koostumus | |
| EP3328844A4 (en) | 1,3,4-oxadiazole sulfamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| IL271807A (en) | New compounds and their pharmaceutical preparations for the treatment of leprosy | |
| EP3231436A4 (en) | Pharmaceutical composition for prevention or treatment of metabolic disease, comprising bacteroides acidifaciens as effective ingredient | |
| EP4327887A3 (en) | Fixed dose combinations and formulations comprising etc1002 and one or more statins and methods of treating or reducing the risk of cardiovascular disease | |
| EP4339192A3 (en) | Compounds and compositions for the treatment of cancer | |
| WO2016006974A3 (en) | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof | |
| WO2016006975A3 (en) | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof | |
| AR109859A1 (es) | Inhibidor de bromodominio | |
| WO2018211324A8 (en) | Prodrugs for the treatment of disease | |
| WO2018211323A8 (en) | Heterocyclic compounds for the treatment of disease | |
| MX2019001771A (es) | Composición farmacéutica sólida que comprende el sofosbuvir amorfo. | |
| EP3530269A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF DIABETES AND / OR HYPERLIPIDEMIA COMPRISING MIDORINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT | |
| HK40068676A (en) | Substituted 1-oxo-isoindoline-5-carboxamide compounds, compositions thereof, and methods of treatment therewith | |
| HK40042859A (en) | Heteroaryl compounds, pharmaceutical compositions thereof, and their therapeutic use | |
| HK40060144A (en) | Co-crystal of ketoprofen, compositions comprising the same, process of producing the same, and uses thereof | |
| HK40019754A (en) | 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases |